Insider Trades107 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 7,576 | $49.23 | $8.2B | -12.21% | +94.20% | $372.9K | -3.56% | 10b5-1 | Buy Now |
| Aug 3, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 2,034 | $48.58 | $8.2B | -12.21% | +94.20% | $98.8K | -0.89% | 10b5-1 | Buy Now |
| Aug 3, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $39.97 | $8.2B | -12.21% | +94.20% | $559.6K | -1.37% | 10b5-1 | Buy Now |
| Jul 6, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 2,034 | $54.03 | $8.2B | -12.21% | +94.20% | $109.9K | -0.89% | 10b5-1 | Buy Now |
| Jul 1, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $40.02 | $8.2B | -12.21% | +94.20% | $560.3K | -1.70% | 10b5-1 | Buy Now |
| Jun 4, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 2,034 | $43.05 | $8.2B | -12.21% | +94.20% | $87.6K | -0.88% | 10b5-1 | Buy Now |
| Jun 1, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $33.70 | $8.2B | -12.21% | +94.20% | $471.7K | -2.30% | 10b5-1 | Buy Now |
| May 29, 2026 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 32,434 | $30.92 | $8.2B | -12.21% | +94.20% | $1.0M | +0.00% | — | Buy Now |
| May 4, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 2,034 | $33.20 | $8.2B | -12.21% | +94.20% | $67.5K | -0.87% | 10b5-1 | Buy Now |
| May 1, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $28.38 | $8.2B | -12.21% | +94.20% | $397.3K | -2.14% | 10b5-1 | Buy Now |
| Apr 6, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 2,034 | $34.57 | $8.2B | -12.21% | +94.20% | $70.3K | -0.86% | 10b5-1 | Buy Now |
| Apr 1, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $29.74 | $8.2B | -12.21% | +94.20% | $416.3K | -2.00% | 10b5-1 | Buy Now |
| Mar 2, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 4,068 | $29.53 | $8.2B | -12.21% | +94.20% | $120.1K | -0.69% | 10b5-1 | Buy Now |
| Mar 2, 2026 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 6,000 | $30.00 | $8.2B | -12.21% | +94.20% | $180.0K | -2.82% | 10b5-1 | Buy Now |
| Mar 2, 2026 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 6,890 | $29.29 | $8.2B | -12.21% | +94.20% | $201.8K | -15.72% | 10b5-1 | Buy Now |
| Mar 2, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $26.01 | $8.2B | -12.21% | +94.20% | $364.2K | -1.19% | 10b5-1 | Buy Now |
| Feb 26, 2026 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 808 | $30.73 | $8.2B | -12.21% | +94.20% | $24.8K | -3.86% | — | Buy Now |
| Feb 26, 2026 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 2,403 | $30.73 | $8.2B | -12.21% | +94.20% | $73.8K | -1.86% | — | Buy Now |
| Feb 26, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 3,049 | $30.73 | $8.2B | -12.21% | +94.20% | $93.7K | -1.19% | — | Buy Now |
| Feb 26, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 3,049 | $30.73 | $8.2B | -12.21% | +94.20% | $93.7K | -2.77% | — | Buy Now |
| Feb 26, 2026 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 3,695 | $30.73 | $8.2B | -12.21% | +94.20% | $113.5K | -1.41% | — | Buy Now |
| Feb 23, 2026 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 672 | $32.19 | $8.2B | -12.21% | +94.20% | $21.6K | -4.30% | — | Buy Now |
| Feb 23, 2026 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 2,845 | $32.19 | $8.2B | -12.21% | +94.20% | $91.6K | -2.33% | — | Buy Now |
| Feb 23, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 3,414 | $32.19 | $8.2B | -12.21% | +94.20% | $109.9K | -1.38% | — | Buy Now |
| Feb 23, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 3,414 | $32.19 | $8.2B | -12.21% | +94.20% | $109.9K | -3.39% | — | Buy Now |
| Feb 23, 2026 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 3,880 | $32.19 | $8.2B | -12.21% | +94.20% | $124.9K | -1.56% | — | Buy Now |
| Feb 18, 2026 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 1,685 | $32.01 | $8.2B | -12.21% | +94.20% | $53.9K | -5.48% | — | Buy Now |
| Feb 18, 2026 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 4,146 | $32.01 | $8.2B | -12.21% | +94.20% | $132.7K | -1.75% | — | Buy Now |
| Feb 18, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 5,533 | $32.01 | $8.2B | -12.21% | +94.20% | $177.1K | -1.13% | — | Buy Now |
| Feb 18, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 6,911 | $32.01 | $8.2B | -12.21% | +94.20% | $221.2K | -3.52% | — | Buy Now |
| Feb 18, 2026 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 7,926 | $32.01 | $8.2B | -12.21% | +94.20% | $253.7K | -1.60% | — | Buy Now |
| Feb 5, 2026 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 6,389 | $33.55 | $8.2B | -12.21% | +94.20% | $214.4K | -5.95% | — | Buy Now |
| Feb 5, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 7,454 | $33.55 | $8.2B | -12.21% | +94.20% | $250.1K | -8.97% | — | Buy Now |
| Feb 5, 2026 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 7,619 | $33.55 | $8.2B | -12.21% | +94.20% | $255.6K | -3.30% | — | Buy Now |
| Feb 5, 2026 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 8,626 | $33.55 | $8.2B | -12.21% | +94.20% | $289.4K | -3.75% | — | Buy Now |
| Feb 5, 2026 | Sell | ALKS | Richard F Pops | Director and CEO, Alkermes plc | 62,230 | $33.55 | $8.2B | -12.21% | +94.20% | $2.1M | -4.32% | — | Buy Now |
| Feb 2, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $28.72 | $8.2B | -12.21% | +94.20% | $402.1K | -1.85% | 10b5-1 | Buy Now |
| Jan 8, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 10,000 | $24.67 | $8.2B | -12.21% | +94.20% | $246.7K | +0.00% | 10b5-1 | Buy Now |
| Jan 2, 2026 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 4,000 | $28.00 | $8.2B | -12.21% | +94.20% | $112.0K | -6.08% | 10b5-1 | Buy Now |
| Dec 3, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 7,496 | $24.67 | $8.2B | -12.21% | +94.20% | $184.9K | +0.00% | 10b5-1 | Buy Now |
| Dec 1, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 4,000 | $29.30 | $8.2B | -12.21% | +94.20% | $117.2K | -5.74% | 10b5-1 | Buy Now |
| Nov 3, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $26.44 | $8.2B | -12.21% | +94.20% | $370.1K | -2.08% | 10b5-1 | Buy Now |
| Oct 15, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,000 | $27.18 | $8.2B | -12.21% | +94.20% | $380.5K | -1.95% | 10b5-1 | Buy Now |
| Aug 3, 2025 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 895 | $26.55 | $8.2B | -12.21% | +94.20% | $23.8K | -0.43% | — | Buy Now |
| Jun 9, 2025 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 6,667 | $31.52 | $8.2B | -12.21% | +94.20% | $210.1K | -3.65% | 10b5-1 | Buy Now |
| Feb 26, 2025 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 2,402 | $34.80 | $8.2B | -12.21% | +94.20% | $83.6K | -2.15% | — | Buy Now |
| Feb 26, 2025 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 2,494 | $34.80 | $8.2B | -12.21% | +94.20% | $86.8K | -1.49% | — | Buy Now |
| Feb 26, 2025 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2,746 | $34.23 | $8.2B | -12.21% | +94.20% | $94.0K | -9.68% | 10b5-1 | Buy Now |
| Feb 26, 2025 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 3,049 | $34.80 | $8.2B | -12.21% | +94.20% | $106.1K | -1.34% | — | Buy Now |
| Feb 26, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 3,049 | $34.80 | $8.2B | -12.21% | +94.20% | $106.1K | -3.01% | — | Buy Now |
| Feb 26, 2025 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 3,695 | $34.80 | $8.2B | -12.21% | +94.20% | $128.6K | -1.61% | — | Buy Now |
| Feb 22, 2025 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 5,398 | $35.28 | $8.2B | -12.21% | +94.20% | $190.4K | -13.84% | 10b5-1 | Buy Now |
| Feb 22, 2025 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 5,741 | $35.32 | $8.2B | -12.21% | +94.20% | $202.8K | -1.89% | — | Buy Now |
| Feb 22, 2025 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 6,003 | $35.32 | $8.2B | -12.21% | +94.20% | $212.0K | -3.08% | — | Buy Now |
| Feb 22, 2025 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 6,714 | $35.32 | $8.2B | -12.21% | +94.20% | $237.1K | -1.60% | — | Buy Now |
| Feb 22, 2025 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 8,185 | $35.32 | $8.2B | -12.21% | +94.20% | $289.1K | -1.98% | — | Buy Now |
| Feb 22, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 8,866 | $35.32 | $8.2B | -12.21% | +94.20% | $313.1K | -5.28% | — | Buy Now |
| Feb 18, 2025 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 1,869 | $35.90 | $8.2B | -12.21% | +94.20% | $67.1K | -1.28% | — | Buy Now |
| Feb 18, 2025 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 1,869 | $35.90 | $8.2B | -12.21% | +94.20% | $67.1K | -1.13% | — | Buy Now |
| Feb 18, 2025 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 2,033 | $35.76 | $8.2B | -12.21% | +94.20% | $72.7K | -4.51% | 10b5-1 | Buy Now |
| Feb 18, 2025 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 2,822 | $35.90 | $8.2B | -12.21% | +94.20% | $101.3K | -0.95% | — | Buy Now |
| Feb 18, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 3,950 | $35.90 | $8.2B | -12.21% | +94.20% | $141.8K | -2.32% | — | Buy Now |
| Feb 18, 2025 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 3,950 | $35.90 | $8.2B | -12.21% | +94.20% | $141.8K | -1.26% | — | Buy Now |
| Feb 12, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 692,955 | $29.02 | $8.2B | -12.21% | +94.20% | $20.1M | -0.45% | 10b5-1 | Buy Now |
| Feb 6, 2025 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 7,399 | $31.39 | $8.2B | -12.21% | +94.20% | $232.3K | -8.68% | — | Buy Now |
| Feb 6, 2025 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 7,514 | $31.39 | $8.2B | -12.21% | +94.20% | $235.9K | -5.33% | — | Buy Now |
| Feb 6, 2025 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 9,752 | $31.39 | $8.2B | -12.21% | +94.20% | $306.1K | -4.92% | — | Buy Now |
| Feb 6, 2025 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 10,647 | $31.39 | $8.2B | -12.21% | +94.20% | $334.2K | -5.54% | — | Buy Now |
| Feb 6, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 15,083 | $31.39 | $8.2B | -12.21% | +94.20% | $473.5K | -19.17% | — | Buy Now |
| Feb 6, 2025 | Sell | ALKS | Richard F Pops | Director and CEO, Alkermes plc | 79,925 | $31.39 | $8.2B | -12.21% | +94.20% | $2.5M | -5.83% | — | Buy Now |
| Jan 30, 2025 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 198,550 | $27.21 | $8.2B | -12.21% | +94.20% | $5.4M | -0.35% | 10b5-1 | Buy Now |
| Dec 9, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 110,148 | $27.90 | $8.2B | -12.21% | +94.20% | $3.1M | -1.26% | 10b5-1 | Buy Now |
| Dec 5, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 9,221 | $31.50 | $8.2B | -12.21% | +94.20% | $290.5K | -13.37% | 10b5-1 | Buy Now |
| Dec 4, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 14,349 | $30.77 | $8.2B | -12.21% | +94.20% | $441.6K | -17.23% | 10b5-1 | Buy Now |
| Nov 27, 2024 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 5,208 | $29.15 | $8.2B | -12.21% | +94.20% | $151.8K | -7.90% | 10b5-1 | Buy Now |
| Nov 11, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 102,054 | $25.84 | $8.2B | -12.21% | +94.20% | $2.6M | -4.30% | 10b5-1 | Buy Now |
| Nov 6, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 10,471 | $29.53 | $8.2B | -12.21% | +94.20% | $309.2K | -9.54% | 10b5-1 | Buy Now |
| Aug 3, 2024 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 895 | $27.72 | $8.2B | -12.21% | +94.20% | $24.8K | -0.52% | — | Buy Now |
| Mar 18, 2024 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 10,417 | $28.10 | $8.2B | -12.21% | +94.20% | $292.7K | -13.65% | 10b5-1 | Buy Now |
| Feb 23, 2024 | Sell | ALKS | Michael J Landine | SVP, Corp Dev., Alkermes, Inc. | 1,811 | $29.57 | $8.2B | -12.21% | +94.20% | $53.6K | -0.61% | — | Buy Now |
| Feb 23, 2024 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 2,587 | $29.57 | $8.2B | -12.21% | +94.20% | $76.5K | -1.04% | — | Buy Now |
| Feb 23, 2024 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 2,845 | $29.57 | $8.2B | -12.21% | +94.20% | $84.1K | -1.37% | — | Buy Now |
| Feb 23, 2024 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 3,231 | $29.63 | $8.2B | -12.21% | +94.20% | $95.7K | -5.39% | — | Buy Now |
| Feb 23, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 3,414 | $29.57 | $8.2B | -12.21% | +94.20% | $101.0K | -1.24% | — | Buy Now |
| Feb 23, 2024 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 3,414 | $29.57 | $8.2B | -12.21% | +94.20% | $101.0K | -1.03% | — | Buy Now |
| Feb 23, 2024 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 3,880 | $29.57 | $8.2B | -12.21% | +94.20% | $114.7K | -1.09% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 908 | $28.91 | $8.2B | -12.21% | +94.20% | $26.3K | -7.16% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | Michael J Landine | SVP, Corp Dev., Alkermes, Inc. | 1,929 | $28.91 | $8.2B | -12.21% | +94.20% | $55.8K | -0.67% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 3,156 | $28.91 | $8.2B | -12.21% | +94.20% | $91.2K | -2.56% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 3,156 | $28.91 | $8.2B | -12.21% | +94.20% | $91.2K | -3.80% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 3,300 | $28.91 | $8.2B | -12.21% | +94.20% | $95.4K | -1.93% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 4,304 | $28.91 | $8.2B | -12.21% | +94.20% | $124.4K | -2.58% | — | Buy Now |
| Feb 22, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 5,452 | $28.91 | $8.2B | -12.21% | +94.20% | $157.6K | -4.43% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | Samuel Joseph Parisi | VP, Finance (Interim PAO) | 1,347 | $31.33 | $8.2B | -12.21% | +94.20% | $42.2K | -7.88% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | Michael J Landine | SVP, Corp Dev., Alkermes, Inc. | 2,914 | $31.19 | $8.2B | -12.21% | +94.20% | $90.9K | -0.22% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 3,248 | $31.42 | $8.2B | -12.21% | +94.20% | $102.1K | -0.52% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 3,594 | $31.32 | $8.2B | -12.21% | +94.20% | $112.6K | -1.55% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 4,863 | $31.08 | $8.2B | -12.21% | +94.20% | $151.1K | -1.49% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 5,966 | $31.56 | $8.2B | -12.21% | +94.20% | $188.3K | -1.89% | — | Buy Now |
| Feb 18, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 8,523 | $31.22 | $8.2B | -12.21% | +94.20% | $266.1K | -3.91% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | Michael J Landine | SVP, Corp Dev., Alkermes, Inc. | 3,183 | $26.77 | $8.2B | -12.21% | +94.20% | $85.2K | -1.17% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | Christian Todd Nichols | SVP, Chief Commercial Officer | 8,135 | $26.77 | $8.2B | -12.21% | +94.20% | $217.8K | -11.63% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | Iain Michael Brown | SVP, Chief Financial Officer | 8,137 | $26.77 | $8.2B | -12.21% | +94.20% | $217.8K | -1.02% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 8,483 | $26.77 | $8.2B | -12.21% | +94.20% | $227.1K | -0.84% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | Blair Curtis Jackson | EVP, Chief Operating Officer | 11,007 | $26.77 | $8.2B | -12.21% | +94.20% | $294.7K | -1.09% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 15,280 | $26.77 | $8.2B | -12.21% | +94.20% | $409.0K | -1.42% | — | Buy Now |
| Feb 8, 2024 | Sell | ALKS | Richard F Pops | Director and CEO, Alkermes plc | 91,757 | $26.77 | $8.2B | -12.21% | +94.20% | $2.5M | -7.22% | — | Buy Now |